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Abstract
The new and rapid advancement in the complexity of biologics drug discovery has been
driven by a deeper understanding of biological systems combined with innovative new
therapeutic modalities, paving the way to breakthrough therapies for previously intractable
diseases. These exciting times in biomedical innovation require the development of novel
technologies to facilitate the sophisticated, multifaceted, high‐paced workflows necessary
to support modern large molecule drug discovery. A high‐level aspiration is a true
integration of “lab‐on‐a‐chip”methods that vastly miniaturize cellulmical experiments could
transform the speed, cost, and success of multiple workstreams in biologics development.
Several microscale bioprocess technologies have been established that incrementally
address these needs, yet each is inflexibly designed for a very specific process thus limiting
an integrated holistic application. A more fully integrated nanoscale approach that
incorporates manipulation, culture, analytics, and traceable digital record keeping of
thousands of single cells in a relevant nanoenvironment would be a transformative
technology capable of keeping pace with today’s rapid and complex drug discovery
demands. The recent advent of optical manipulation of cells using light‐induced
electrokinetics with micro‐ and nanoscale cell culture is poised to revolutionize both
fundamental and applied biological research. In this review, we summarize the current
state of the art for optical manipulation techniques and discuss emerging biological
applications of this technology. In particular, we focus on promising prospects for drug
discovery workflows, including antibody discovery, bioassay development, antibody
engineering, and cell line development, which are enabled by the automation and
industrialization of an integrated optoelectronic single‐cell manipulation and culture
platform. Continued development of such platforms will be well positioned to overcome
many of the challenges currently associated with fragmented, low‐throughput bioprocess
workflows in biopharma and life science research.
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1 | INTRODUCTION OF LIGHT‐ INDUCED
ELECTROKINETICS AND IMPACT ON
BIOLOGICS DISCOVERY
A new generation of techniques based on forces exerted by a light
beam (known as optical manipulations) is enabling interactive biology
at the cellular level, thus opening new opportunities in drug
discovery. Optical manipulation—which enables highly selective and
dynamic processes in micro‐ and nanoscopic systems—has proven to
be a versatile and integrated technology throughout many scientific
areas. This technology is based on light‐induced electrokinetics that
gives rise to designated forces on both solid and fluidic structures.
Since the discovery of the optical gradient and scattering forces in
1970 by Ashkin et al. (1970) a wide variety of optical manipulation
methods have been developed including optical tweezers, plasmon‐
based optical trapping/plasmonic tweezers, and optoelectronic
tweezers (OET).
Optical tweezers utilize radiation pressure and gradient force
from a single laser beam, focused by a high numerical aperture
microscope objective, to trap and manipulate micro‐sized particles
with forces at piconewton scales and nanometer range distances,
(Figure 1a; Ashkin, 1970; 1992; Ashkin, Dziedzic, Bjorkholm, & Chu,
1986; Grier, 2003). Through the use of holographic optical tweezers,
the ability to manipulate multiple particles in parallel has been
enabled and advanced by the Grier and Dufresne labs (Curtis, Koss, &
Grier, 2002; Dufresne, Spalding, Dearing, Sheets, & Grier, 2001;
Mejean, Schaefer, Millman, Forscher, & Dufresne, 2009; Polin,
Ladavac, Lee, Roichman, & Grier, 2005). As a result, optical tweezers
have become a primary methodology for a variety of physical,
chemical, and biological experiments. In particular, their capability to
achieve highly accurate measurements on spatial (sub‐nanometer)
and temporal (sub‐millisecond) regimes has ranked them as one of
the forefront single‐molecule manipulation techniques with a wide
range of applications (Fazal & Block, 2011; Moffitt, Chemla, Smith, &
Bustamante, 2008; Neuman & Block, 2004; Neuman & Nagy, 2008;
Pang & Gordon, 2011). Figure 1b shows an example of optical
tweezers applied to the study of nanomechanical properties of
double‐stranded DNA (Fazal & Block, 2011). A thorough review of
the theory and practice of optical tweezers across multiple size scales
and applications has been presented by Polimeno et al. (2018).
To further extend nanoscale optical trapping and overcome the
diffraction limitations on spatial confinement associated with optical
tweezers, plasmonic optical tweezers (POT) were developed (Juan,
Righini, & Quidant, 2011; Miao & Lin, 2007; Reece, 2008; Shoji &
Tsuboi, 2014). This approach combines optical tweezers with
nanostructured gold substrates resulting in localized surface plas-
mons (Figure 1c). The tightly spaced surface plasmons generate a
strong electric field enhancement and radiation pressure and enable
stable optical trapping of particles at the nanoscale range. POTs
facilitate efficient trapping of nanoparticles with laser intensities
weaker than conventional optical tweezers (Figure 1d). In addition,
the tailored design of the nanostructured substrates allows precise
nanoscale control of the motion of nanoparticles.
Conventional and plasmonic optical tweezers have become
powerful tools in biology allowing high‐resolution experiments on
trapped single cells. However, both are limited to a small manipula-
tion area due to large optical intensity requirements generated via
high‐power lasers (at least 104W/cm2)11. In addition, the high optical
power density causes cell damage over time and limits the duration
of experiments. To overcome these limitations, a novel optical
manipulation technique known as OETs was developed. OET enables
massively parallelized optical manipulation of single cells via the
utilization of optical beams to generate patterned virtual electrodes
on a photoconductive material (Chiou, Ohta, & Wu, 2005; Hsu et al.,
2010; M. C. Wu, 2011). OET operates within a much lower optical
intensity (3W/cm2) over a much larger addressable area (up to
11mm2 as demonstrated on commercially‐available OET platforms
(Berkeley Lights Inc.) with the installed Nikon 4×, 0.28NA objective.
A schematic of OETs is shown in Figure 1e demonstrating their
operating principle (M. C. Wu, 2011). Structurally, it consists of a top
transparent indium‐tin‐oxide (ITO) electrode and a bottom photocon-
ductive hydrogenated amorphous silicon (a‐SI:H) electrode, separated
by a fluidic chamber. The combination of patterned illumination and an
applied AC bias between the two electrode layers generates a localized
electric‐field gradient. Specifically, the electric‐field gradient results
from the many orders of magnitude increase in conductivity of the a‐
Si:H electrode layer when illuminated. This results in the creation of
electron‐hole pairs in the electrode layer causing the voltage to drop
across the fluidic chamber. In turn, objects such as particles or cells,
experience dielectrophoresis (DEP) force in the presence of the light‐
induced electric‐field gradient. The force FDEP applied to a particle with
radius a is proportional to the electric field E applied (Zhang, Nikitina
et al., 2018). The force can be positive (attractive) or negative (repulsive)
depending on the relative values of the complex permittivity of the
media mϵ⁎ and particle pϵ⁎ (Q. Chen & Yuan, 2019).
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Thus, OETs enable full control of the position and motion of
particles in the fluidic chamber by changing the light pattern through
a digital light projector. An “optical conveyor belt” is shown in the top
of Figure 1f. The OET with amorphous silicon photoconductor can
only operate in media with conductivity <0.1 S/m. Typical cell culture
media or physiological buffers have conductivities of approximately
1.4 S/m. To overcome this limit, the amorphous silicon
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F IGURE 1 Optical manipulations | (a) Schematic of single‐beam optical tweezers: Particles as small as tens of nanometers are trapped by an
optical gradient force generated via a high‐intensity laser (105 to 107W/cm2; Grier, 2003). (b) Example of a nucleic acid system studied using
optical tweezers, showing nanomechanical properties of filaments subjected to twist: The relative extension of DNA is monitored as trapped DNA
is twisted with an optical torque wrench. The coiled DNA undergoes a phase transition from a twisted to a plectonemic form approximately 0.14
supercoiling density (Fazal & Block, 2011). (c) Plasmonic tweezers schematic: Patterned gold nanopillars give rise to localized surface plasmons
causing a strong field enhancement under the trapping beam and suppression of the Brownian motion (characteristic of POT) resulting in improved
particle confinement (Reece, 2008). (d) Molecular manipulation via plasmonic tweezers: A single bovine serum albumin (BSA) protein is trapped in
the gap of a double hole nanostructure (Pang & Gordon, 2011). (e) Schematic of an optoelectronic tweezer device consisting of: a photoconductive
layer of hydrogenated amorphous silicon (a‐Si:H) on an indium tin oxide (ITO) coated glass substrate (bottom layer), a liquid containing
microparticles is sandwiched between the bottom layer and the top ITO‐coated glass layer. An AC electrical signal between the top and bottom
layers in combination with patterned illumination create a nonuniform electric field that results in particle manipulation via dielectrophoresis (DEP;
M. C. Wu, 2011). (f) Top image shows 20‐micron polystyrene particles confined in patterned light cages. Bar = 20 μm; Bottom image of shows
virtual electrode cages (yellow) formed from projected light pattern to precisely control the position of individual cells. Bar = 50 μm (Hsu et al.,
2010; M. C. Wu, 2011). POT, plasmonic optical tweezers [Color figure can be viewed at wileyonlinelibrary.com]
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photoconductor is replaced by single crystalline phototransistor (M.
C. Wu, 2011). The phototransistor has 500x higher conductivity than
amorphous silicon when illuminated. This allows long‐term culturing
of cells and direct observation of the heterogeneity of doubling rates
among the cells, bottom of Figure 1f (Hsu et al., 2010). As shown in
Figure 1f, high‐resolution patterned illumination results in accurate
single‐cell encapsulating compartments, which can also define their
motion. OETs overcome many limitations associated with other light‐
based techniques for micro‐particle manipulation, particularly in
biological applications. First, OETs require a significantly low optical
power (10−1W/cm2) in comparison to conventional and plasmonic
tweezers (104–106W/cm2), making them noninvasive to achieve cell
control and motion without compromising cell viability. Secondly, the
low optical power requirements eliminate the necessity of a high
numerical aperture objective to tightly focus a high‐power laser,
which otherwise limits the area of particle control and manipulation.
OETs significantly increase the manipulation area by two orders of
magnitude in comparison to optical tweezers via the utilization of a
10x objective and a light‐emitting diode (LED) as the illumination
source, thus facilitating high‐throughput processes (Chiou et al.,
2005). Thirdly, the advancement from structural to high‐resolution
virtual electrodes enables massively parallel and dynamic single‐cell
manipulation.
2 | BIOLOGICAL APPLICATIONS OF OETs
The utility of OET for particle and cell manipulations has led to a wide
variety of advanced OET‐based devices and biological applications.
Different approaches in the utilization of OET at the on‐the‐bench level
resulted in a wide variety of applications including: manipulation of
nano‐ and micro‐beads (Glaesener, Esseling, & Denz, 2012; Hsu et al.,
2010; Ohta et al., 2007; Ota, Wang, Wang, Yin, & Zhang, 2013; Valley,
Pei, Jamshidi, Hsu, & Wu, 2011; Williams, Kumar, Green, & Wereley,
2009), droplets (Pei, Valley, Wang, & Wu, 2015), nanowires (Jamshidi
et al., 2008), and diverse biological cells (Jeorrett et al., 2014; Neale
et al., 2009; Ohta et al., 2010; Park, Teitell, & Chiou, 2010; Shah, Ohta,
Chiou, Wu, & Kim, 2009; Valley et al., 2009; Verma et al., 2014; Y. Yang,
Mao, Shin, Chui, & Chiou, 2016). Figure 2 displays three examples of
forward‐thinking OET‐based platforms.
Valley et al. (2011) developed a versatile device facilitating on‐chip
particle and droplet manipulation via the integration of OETs with
optoelectrowetting. This unified platform enabled serial particle
concentration, resulting in an exponential increase in particle concen-
tration that can be utilized for on‐chip sample concentration/purifica-
tion (Figure 2a). In addition, the device has the ability to encapsulate
single cells in microscale droplets of cell culture media, paving the way
towards cell manipulation and analysis in a more relevant environment
when compared with previous electrowetting concepts that required
low conductivity buffer (Figure 2b; Hsu et al., 2010; Valley et al., 2011).
A proof‐of‐concept experiment demonstrated the unified platform’s
ability to form a high‐density array of droplets and was applied in the
biomedical application of viral detection (Figure 2c; Pei et al., 2015).
Another OET‐based device integrated with microfluidic channels and
chambers has been developed for high‐throughput and high‐selectivity
electroporation of individual cells (Valley et al., 2009). A schematic of
the device is shown in Figure 2d: lithographically defined channels were
integrated with the OET device enabling light‐induced electroporation,
maintenance of viable cell cultures, and perfusion of different soluble
reagents. Electroporation was performed on HeLa cells using the
membrane impermeant dye, propidium iodide (PI; Valley et al., 2009).
Initially, low OET bias (0.2 kV/cm) was used to position individual cells in
specified locations, followed by application of high electroporation bias
(1.5 kV/cm) to selected cells resulting in the intracellular delivery of the
PI dye (Figure 2e). In addition to electroporation, single cell lysis using
OET has also been demonstrated (Kremer et al., 2014; Witte et al.,
2014). Lastly, a device based on a novel concept, Self‐Locking
Optoelectronic Tweezers (SLOT), has shown promising results in
scaling up single‐cell manipulation across a significantly larger area
(Y. Yang et al., 2016). The device schematic, Figure 2f, shows a
prototype array of ring‐shaped phototransistors that control particle/
cell trapping. A unique feature of the SLOT platform is the Al2O3
(an insulating dielectric layer) coating the surface to partially drop the
voltage, enabling the single‐cell self‐locking function in high conductivity
media. A device consisting of 250,000 phototransistor traps over a
1‐cm2 area has been shown to enable simultaneous trapping of over
100,000 polystyrene beads. Furthermore, the device enables the
selective release of trapped particle via a scanning light beam as shown
in Figure 2g, resulting in the formation of four letters standing for UCLA
(Y. Yang et al., 2016). Another recent improvement called patterned
optoelectronic tweezers enables more flexible particle manipulation by
exposing the electrode layer in specific patterns that will hold particles
after the light source is removed (Zhang, Shakiba et al., 2018).
Additional methods to retain particles after light removal include the
use of microwells to observe the interactions between cancer cells and
immune cells (Ke et al., 2017). The schematic diagram of the four‐leaf‐
clover‐shaped chip, Figure 2h, depicts the design of the immunotherapy
µ‐environment LabChip. The stable and static µ‐environment enabled
the accumulation of secretions from natural killer cells for real‐time
analysis of their behavior on adjacent cancer cells (Figure 2i‐k).
The advanced OET‐based devices described above offer a wide
variety of potential applications, including single‐cell studies invol-
ving multiplexed environmental stimuli, high‐throughput, and
high‐resolution genetic transfection, study of cell‐to‐cell signaling,
tissue engineering, in vitro fertilization, immunotherapy, and beyond.
However, these platforms have been limited to proof‐of‐concept
experiments at the bench level.
3 | INDUSTRIALIZATION OF
PARALLELIZED SINGLE‐CELL
MANIPULATIONS
The broad potential applications of OET have led to the development
of an industrial platform, Beacon®, which incorporates opto‐electro‐
positioning (OEP) technology, a variation on the OET technology, into
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FIGURE 2 Continued.
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an automated standalone system shown in Figure 3a. The system can
be broken up into three key components: hardware, software, and
consumables (chips and reagents). The hardware itself is approxi-
mately the size of a large refrigerator and requires power (120 V) and
gas lines (CO2, house air, and optional O2) to operate, as well as an
optional Ethernet port. An optical module consisting of an epifluor-
escent microscope with LED illumination and a custom digital mirror
display for creating patterned illumination is situated above a
motorized stage in the “sample bay” (Figure 3a,b). This three‐axis
motorized stage holds four individual “nests” for housing up to four
separate “chips.” Each nest has independently controlled tempera-
ture (15–40°C), using liquid‐cooled thermoelectric devices, as well as
independent fluidic lines to control fluid exchange. Each nest has a
dedicated syringe pump, located in a separate “reagent bay.” Each
chip also has a “needle” that is independently actuated in the
z‐direction for both input and output of media or reagents. A fifth
syringe pump, also located in the reagent bay, is connected to a fifth
input/output needle and can be used as a liquid handling robot. All of
the input/output needles are situated above two “well plate incubators”
(WPIs) in the sample bay. Each WPI acts as a miniature incubator, sized
to hold a single 96‐well plate with temperature control (15–40°C) and is
supplied with humidified air with specified CO2 and O2 content
(0–20%). The WPIs hold separate 96‐well plates which provide both
cells and reagents for importing into individual chips. These same WPIs
are also used for exporting cells and are designed to keep cells in a
suitable culture environment for at least 24 hr to maximize the
flexibility of the system and eliminate the need for constant human
supervision. The reagent bay holds the media used for on‐chip cell
culture as well as reagents for cleaning in between runs. Below the
reagent bay is the “waste module” for collecting all liquid waste.
Underneath the sample, bay resides the electrical compo-
nents, which include the computer. Custom software controls all
aspects of the system, with the main user interface being a large
touchscreen monitor situated just above the sample bay. The
chips are fabricated using semiconductor manufacturing technol-
ogy whereby an array of phototransistors is patterned on a
silicon substrate, which will become the floor of the microfluidic
channels. Walls are created using photolithography and the
ceiling consists of an ITO‐coated glass cover. These three layers
are bonded together to form a chip which is mounted on a printed
circuit board (PCB) that provides electrical connections as well as
an EEPROM for storing identifying details for each chip.
Within each chip, there are a series of parallel fluidic channels
with rows of NanoPen chambers situated along one side. The
NanoPens are photolithographically defined structures that create
unswept regions that are protected from shear flow, which can be
created in the main fluidic channels by means of a corresponding
syringe pump. These NanoPen chambers are connected to the main
channels through a small opening (typically 50 µm wide and 40 µm
tall). Due to the small scales, the inside of the NanoPens do not
experience any convective mixing, rather any mass exchange
between the channels and pens is dominated by diffusion.
Figure 3d shows a chip with a representative fluidic structure, along
with details on the two NanoPen structures that we have focused on
for this study. The ability to create unswept chambers with nanoscale
volumes that are still connected to a swept channel is crucial to
creating a microenvironment suitable for robust cell growth while
maintaining spatial separation of single cells or clones. Cells are much
too large to effectively diffuse into or out of the NanoPens, but single
cells can be deposited into individual chambers using light‐induced
DEP. Once placed in a NanoPen, the cell remains unaffected by the
shear forces in the main channel that are driven by the syringe pump;
however, nutrients and/or waste products are free to enter/exit via
diffusion, enabling a continuous perfusion culture system that
enables simultaneous viewing of the growth of thousands of
individual clones on a single chip.
F IGURE 2 OET Bench‐scale applications | (a) Schematic of serial particle concentration: A light pattern is swept across the device
concentrating beads at one end of the droplet via OET, followed by droplet splitting via OEW. Reiteration of this process results in an
exponential increase in particle concentration (Valley et al., 2011). (b) Schematic of single cell selection and encapsulation: Patterned lights
move specified cells in opposite sides of the droplet via OET, followed by droplet splitting via OEW resulting in a droplet with the single cell of
interest (Valley et al., 2011). (c) A 4 × 4 array of droplets is formed by selectively positioning eight positives and eight negative controls. The
negative control droplets contain blank viral transport medium while the positive control droplets contain 1.45 × 103 viral‐particles/nl. No
cross‐contamination was observed in the fluorescent image of the polymerase chain reaction (PCR) amplified products (Pei et al., 2015). (d)
Schematic of light‐induced electroporation device: a top substrate is coated with the transparent conductor indium tin oxide (ITO), a middle
layer consists of patterned SU‐8 layer defining the channel geometry, while bottom substrate coated with ITO and a photosensitive film (a‐Si:H;
Valley et al., 2009). (e) First cells are positioned in a 2 × 2 array via low bias OET (0.2 kV/cm), first column, followed by a high bias (1.5 kV/cm)
two‐step electroporation of specific cells. Fluorescent images show that only selected cells were electroporated, resulting in selective
intracellular delivery of the membrane impermeant PI dye (Y. Yang et al., 2016). (f) Schematic of self‐locking optoelectronic tweezers (SLOT)
consisting of a high‐density array of ring‐shaped electrodes, each controlled via an underlying phototransistor (Y. Yang et al., 2016). (g)
Polystyrene beads (8‐μm) trapped in parallel on a 1 cm2 SLOT platform with more than 250,000 phototransistor traps. Initially, the particles are
randomly distributed, next applied AC voltage between the top and bottom layer results in particle self‐locking into nearby traps. A scanning
light beam selectively releases trapped particles, as shown through the formation of four letters – UCLA (Y. Yang et al., 2016). (h) Schematic of
TiOPc‐based immunotherapy µ‐environment LabChip: consisting of PEG‐DA hydrogel four‐leaf‐clover‐shape (FLCS) microwells to generate a
biomimetic environment (Ke et al., 2017). (i) Real‐time analysis of NK cell’s behavior. Representative images showing NK cell and target cell
morphologies over time to track immune cell cytotoxicity (Ke et al., 2017). (j) Percentage of target cells killed at a 1:1 ratio of NK cells: Target
Cells (Ke et al., 2017). (k) Percentage of target cells killed at a 10:1 ratio of NK cells: Target Cells (Ke et al., 2017). NK, natural killer; OET,
optoelectronic tweezer; OEW, optoelectrowetting; PI, propidium iodide [Color figure can be viewed at wileyonlinelibrary.com]
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4 | APPLICATIONS IN
BIOPHARMACEUTICAL INDUSTRY
The integrated technology has the flexibility and capability to enable
a broad array of applications applicable to commercial large molecule
drug development, including antibody discovery, clonal selection,
gene editing, linking phenotype to genotype, and cell line develop-
ment. We explored a wide variety of cell‐based discovery and
optimization processes while simultaneously developing new assays
focused on quantitative data readouts. In particular, we developed
F IGURE 3 Platform technology: Beacon® | (a) Representative image of the instrument consisting of four bays: sample and chip, electronics,
reagents, and waste. Dimensions: 42”W 32”D 72”H. (b) Schematics of the optical system: Camera: Andor Zyla; Filter changer: DAPI (Ex 390/40,
DC BLTS‐0025), Em 452/45, FITC (Ex 475/50, DC 509‐FDi01, Em 540/50), TxRED (Ex 562/40, DC BLTS‐0026, Em 624/40), Cy5 (Ex 628/40,
DC BLTS‐0027, EM 692/40), OEP (Ex 405R, DC 90R/10T, Em BLTS‐0030); Objective changer: Olympus Xfluor 4×/0.28 WD29mm, Nikon Plan
Fluor 10×/0.30 WD 16mm. (c) Sample bay hosting four nests, optics, camera, robotics, and plate incubators. (d) Representative image of a chip
and the schematics of its fluidic structure. NanoPen structures associated with two different chip designs facilitate a variety of processes at
different dimensions. OEP, opto‐electro‐positioning [Color figure can be viewed at wileyonlinelibrary.com]
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techniques for the manipulation and monitoring of isolated individual
cells of yeast, hybridomas, B cells, Chinese hamster ovary (CHO),
HEK293T, and HepG2. In addition, other groups have demonstrated
the ability to select CRISPR edited clones as well as the ability to link
phenotype to genotype, both on single cell levels and using T‐cells
and tumor cells (Beaumont et al., 2018; Mocciaro et al., 2018). The
process integration enabled by this platform technology has paved
the way towards the acceleration of large molecule identification and
optimization, relative to conventional methods and technologies.
5 | ANTIBODY DISCOVERY
Traditionally, the discovery of mAbs derived from hyperimmunized
animal models has relied on immortalization of the antibody‐
secreting cell (ASC) via hybridoma technology (Akagi, Nakajima,
Tanaka, & Kurihara, 2018; Basalp & Yucel, 2003; Y. Chen et al., 2018;
Kohler & Milstein, 1975; Li et al., 2018), viral immortalization of the B
cell directly (Kwakkenbos et al., 2010; Traggiai et al., 2004), or phage
and yeast display of antibody fragments derived from cloning of the
antigen‐experienced B cell mRNA repertoires (Chan, Lim, MacAry, &
Hanson, 2014; Dong, Bo, Zhang, Feng, & Liu, 2018; Feldhaus & Siegel,
2004; Glumac et al., 2018; Grzeschik et al., 2019; Scholler, 2018).
Although these methods are well validated for both drug discovery
and reagent antibody generation, commercial‐scale application
requires significant laboratory infrastructure, large‐scale plate‐based
aseptic liquid handling automation platforms, and lengthy workflows
dependent on mitotic doubling times to generate antibodies with
commercial value. It is therefore obvious that antibody discovery
techniques that enable direct B cell screening without the need for
immortalization or transformation are of great interest. Direct B cell
discovery techniques offer the potential to reduce development
timelines, recover repertoires of functionally relevant IgG directly
from B cells compartments not normally sampled (i.e., bone marrow),
reduce or even eliminate altogether costly plate‐based aseptic liquid
handling automation, and discover novel antibodies from species
without traditional fusion partners (e.g. chickens, llamas, sharks). In
addition, single B cell techniques that preserve the endogenous
variable heavy (VH) and variable light (VL) pairing of the in‐vivo
affinity matured IgG through the process, as opposed to high‐
throughput DNA sequencing and rebuilding IgGs based on relative
VH and VL frequencies (Reddy et al., 2010), may offer a more direct
route to commercial antibody discovery.
A number of different single‐cell screening approaches have
emerged over the years to address this opportunity. Comprehensive
review papers describing these technologies have been published
previously (Fitzgerald & Leonard, 2017; Seah, Hu, & Merten, 2018;
Voigt, Semenova, Yamamoto, Etienne, & Nguyen, 2018), nonetheless
brief introductions for a select few of these will again be presented
here. FACS sorting of specific B cell subsets, plate‐based multiplex
PCR, and recombinant antibody expression in suitable host cells have
effectively recovered IgG sequences directly from select B cell
subsets of both C57BL/6 wild‐type mice(Jin et al., 2009) and humans
(Wrammert et al., 2008; X. Wu et al., 2010). Mettler‐Izquierdo et al.
(2016) presented the gel encapsulated microenvironment (GEM)
technique capable of interrogating up to 100 million B cells from
hyperimmunized animals directly for antigen specificity. A relative of
the fluorescent foci techniques (Babcook, Leslie, Olsen, Salmon, &
Schrader, 1996; Tickle et al., 2009), the GEM technique encapsulates
B cells of interesting in emulsion droplets using a mixture of agarose
and dimethylpolysiloxane combined with either antigen‐coated beads
and/or reporter cells expressing membrane antigens. Manual
fluorescent microscopy is used to analyze the binding properties
and localization of any secreted IgGs while physical recovery of the
desired B cell is performed via manual picking using a micropipette.
Microfluidic arrays generated via soft lithography microengraving
have also been successfully used to isolate and screen monoclonal
antibodies directly from B cell subsets without immortalization
(DeKosky et al., 2013; Jin et al., 2009; Love, Ronan, Grotenbreg, van
der Veen, & Ploegh, 2006; Story et al., 2008). These techniques are
based on chip array technology combined with modifications to
classical ELISPOT and/or ELISA techniques. In addition to isolating
single cells at scales between 103 to 105, they offer the ability to
screen directly against the antigen of interest and in some instances
perform relative characterizations for key attributes such as binding
affinity (Story et al., 2008). When combined with single cell PCR for
VH and VL recovery and recombinant expression, panels of antigen‐
specific monoclonal antibodies derived from these approaches can
effectively be recovered within 1 to 2 weeks from the time of animal
harvest. Nonetheless, not all labs are properly equipped to generate
microarrays and for those that are, manual retrieval of the cells from
these microarray systems still remains a fundamentally time‐
consuming and highly specialized process.
Despite their innovative power and a diverse set of advantages
over traditional hybridoma and display methodologies, there are a
couple of common features that the above‐mentioned methods lack.
The first is the ability to effectively culture nonimmortalized ASCs as
single cells and maintain them in a viable antibody secreting state for
multiple days. The terminally differentiated state of ASCs combined
with their relatively fragile nature limits the amount of iterative IgG
characterization that can be performed on a given set of ASCs.
Recovering and recombinantly expressing IgGs that are lacking
characterization data for key attributes such as binding affinity,
cross‐species reactivity, or functional activity can translate into large
and costly cloning and expression efforts and may ultimately fail at
meeting the design goals for a specific discovery campaign. The second
is the lack of an integrated system for digital record keeping of both
images and raw numerical data from important processing steps in an
antibody discovery workflow. Clonality and viability are key attributes
in single cell workflows and of course, data integrity is a fundamental
requirement for establishing intellectual property on novel inventions.
A fully integrated direct B cell screening and recovery system that
combines speed, sensitivity, characterization depth, ease of use, and
workflow automation while simultaneously capturing digital records at
each step of the screening workflow, therefore, could represent a
quantum leap forward for commercial antibody discovery.
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Using the Beacon platform technology, we have developed a
nanofluidic optoelectronic B lymphocyte screening technique
(NanOBlast) that enables direct screening of secreted immunoglo-
bulins from ASCs harvested from hyperimmunized wild‐type mice
(Figure 4; Winters (2019). Rapid Single B Cell Antibody Discovery Using
Nanopens and Structured Light. Manuscript submitted.). The process
includes a magnetic negative selection to remove non‐B cells and a
FACS‐based positive selection enrichment protocol to enrich for
ASCs to address the low‐frequency distribution of antigen‐specific
ASCs found in murine spleen and lymph node compartments. Using
the tunable OEP parameters and customizable culture conditions on
the platform, we effectively isolated single ASCs into nanopens while
maintaining their viability. Within an hour of loading the ASCs, we
executed two color soluble antigen bead‐based assays screening
assays to simultaneously identify IgG producing and antigen‐specific
ASCs. The 0.74 nanoliter volume of the nanopens in the OptoSelect™
3500 chip combined with ASC secretion rates in the 10–1000 s of
IgG/sec (Henn et al., 2009) allowed antigen‐specific IgG detection of
most ASCs within 10 to 15min. Exploiting the rapid turnaround time
of the assays and the continued viability of the ASCs in the nanopens,
we ran a second screen with a reduced concentration of the antigen
to identify those ASCs secreting IgG with higher relative affinity.
Selected ASCs were then exported out of the chip using the OEP and
precision pump system of the platform directly into 96‐well plates
containing lysis buffer. VH and VL sequences were recovered using a
modified 5′ RACE and expression constructs synthetically built for
downstream cloning, recombinant expression, and thorough antigen
binding characterization.
Using the Beacon platform, single ASCs of interest can be
effectively imported, cultured, screened and exported from the
NanoPens of the microfluidic chip with precise control. Depending on
the degree of characterization desired, ASCs can be cultured on‐chip
for multiple days while iterative screening assays are executed.
Although the data presented here only shows two back‐to‐back
assays with two color multiplexing, one can imagine methods to
expand the on‐chip characterization. For example, iterative four color
multiplex bead assays could profile an individual ASC for reactivity to
human, cyo, mouse and rat versions of a protein and so across
multiple concentrations. Perhaps more exciting is using the micro-
fluidic culture abilities of the Beacon to perform on‐chip assays
directly for antibody function. Coculture experiments interrogating
ligand blocking, signal transduction, receptor internalization, and
agonism of functional target cells could potentially be of great value.
As the Beacon technology matures, it will undoubtedly offer unique
opportunities to transform antibody discovery workflows for both
reagent as well as therapeutic applications.
6 | OPTIMIZATION OF LARGE MOLECULES
The development of large molecule therapeutics with optimal
potency, selectivity, and biophysical properties often requires the
F IGURE 4 Primary ASC based antibody discovery | (a) Workflow overview: Immunization schedules designed to enhance the relative
frequency of ASCs in specific compartments. Specific organ compartments were harvested, and ASCs enriched using magnetic bead negative
selection followed by a multicolor FACS sorting strategy. Iterative multiplex screens were performed on the OEP platform. Selected hits were
exported, the VH and VL sequences recovered via multiplex PCR, and the IgGs recombinantly expressed for further characterization. (b) Multiplex
bead‐based assay design for soluble antigens: Bead size, antigen, secondary antibodies and detection fluorophore were chosen to specifically
enable robust identification of antigen‐specific ASCs. (c) Images of IgG secreting (TRed) antigen‐specific (Cy5) B cells at two concentrations of
antigen. (d) Percentages of IgG+ and antigen+ wells identified from enriched normal mouse ASCs as a function of time on chip. ASCs, antibody‐
secreting cell; OEP, opto‐electro‐positioning; PCR, polymerase chain reaction [Color figure can be viewed at wileyonlinelibrary.com]
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generation and screening of many engineered antibody variants
(Chiu & Gilliland, 2016). Depending on the properties desired in the
final molecule, these engineering designs may target affinity or
selectivity modulation (Kiyoshi et al., 2014; Sellmann et al., 2016;
Tiller et al., 2017), reduction in immunogenicity (Presta, 2006), better
pharmacokinetics (Haraya, Tachibana, & Igawa, 2019; Hotzel et al.,
2012), removal of chemically labile sites (Chelius, Rehder, &
Bondarenko, 2005; DiCara et al., 2018; Haberger et al., 2014), and/
or improvement in other biophysical properties related to manufac-
turing (Jarasch et al., 2015; Seeliger et al., 2015; Xu et al., 2013).
Standard methods of screening panels of molecules that have been
engineered for multi‐parameter optimization require cloning, expres-
sion, and purification of a sufficient quantity of protein to run
multiple assays. This workflow is labor‐intensive and limits the
number of designs that can be tested in a reasonable amount of time
(Barnard, Hougland, & Rajendra, 2015; Bos et al., 2014; Estes et al.,
2015; Schmitz et al., 2019; Winters, Chu, & Walker, 2015; X. Yang
et al., 2013; Yoo, Provchy, Park, Schulz, & Walker, 2014).
To address these limitations, we explored the development of a
prescreen process on the OEP platform based on automated
manipulation and analysis of nanoliter‐scale expression cultures of
transfected antibodies. Very rapid screening of transfected cultures
is possible because the platform allows for loading multiple cells per
pen in addition to single‐cell loading. Initially, we focused on
reducing timeline and resources necessary for screening engineered
mAb panels by implementing assays to quickly identify and
eliminate poor expressors and poor binders. Two relative titer
ranking (RTR) assays were developed, either diffusion‐based
(in‐pen) or bead‐based (in‐channel), to evaluate IgG secretion levels
of both transiently transfected HEK 293‐6E cells (Durocher, Perret,
& Kamen, 2002) and stably transfected and selected CHO pools.
The in‐pen assays are based on a fluorescently‐labeled peptide that
binds specifically to human IgG1 Fc, Spotlight™ huIg (Berkeley
Lights, Emeryville, CA). The Spotlight reagent is imported onto chips
loaded with antibody‐expressing cells and then flushed away after a
short incubation. Because mAb‐bound peptide diffuses more slowly
than free peptide, the amount of fluorescence remaining in each pen
after an optimized flush time is proportional to the amount of IgG
secreted by the transfected cells. We also developed an in‐channel
assay for IgG secretion in which polystyrene beads coated with
goat anti‐human IgG are imported onto the chip along with a
fluorescently‐labeled secondary antibody and monitored over time.
Unlike the diffusion‐based assay, in which fluorescent images are
acquired at a single time point after flushing out the free label, the
bead‐based assay can report on the kinetics of IgG secretion from
each culture through the acquisition of images at multiple time
points. In both assay formats, bright field images are used to
eliminate pens without cells, allowing accurate ranking of molecule
expression by calculating the fraction of pens secreting IgG for each
antibody variant (Figure 5b).
For ease of assay optimization workflow, our initial experiments
were conducted using stable CHO pools that had been selected for
the integration of the transgenes using resistance markers. However,
approximately 8 to 10 days required for cell recovery would add
significantly to the overall timeline for an engineered antibody
screening process. Therefore, we focused our further development
on transient transfection systems, which shortened the process
timeline from 15 days to 3 days. In our HEK 293‐6E transient
transfection process, we loaded cells 24 hr after transfection and
succeeded in detecting secreted antibodies within 2 hr after cell
loading and through the following 24 hr (Figure 5a). The on‐chip RTR
assay results for IgG secretion from these rapid transient expressions
correlate with mAb titer from standard expression cultures as
measured by the FortéBio Octet® system, similar to the RTR rankings
from stable CHO process (Figure 5b). Because the exquisite
sensitivity of the assay delivers robust results at early time points,
we are able to implement a transient workflow that significantly
reduces the timeline for evaluation of relative expression levels of
engineered variants.
To further expand the characterization capabilities of the
platform technology for engineered antibodies, we also estab-
lished a diffusion assay for binding affinity to target antigen. In
the example shown in Figure 5c, we developed and optimized an
assay for on‐chip specific antigen binding to the soluble
extracellular domain (ECD) of a G‐protein‐coupled receptors
(GPCR). We transiently transfected HEK 293‐6E cells with 10
different anti‐GPCR antibodies with known binding affinity and
evaluated their ability to bind fluorescently‐labeled soluble
antigen 24 hr posttransfection. We imported and incubated
1 µg/ml fluorescently‐labeled antigen for 25 min, flushed for
8 min, and assessed the amount of label remaining in each pen
via image acquisition. As shown in Figure 5c, the on‐chip antigen
diffusion assay for this panel of engineered antibodies showed a
promising correlation with binding affinity measured by KinExA.
The combined analysis of IgG secretion and antigen diffusion
assays enables the differentiation of high affinity versus low‐
affinity binders and very rapid deselection of the worst variants
in an antibody panel. More quantitative rankings using time‐
based analysis of the intensity level per specified location are
currently in development.
We demonstrated that the integrated technology of the platform
enables expressing and assaying engineered antibodies on the
nanofluidic chip in a streamlined process. Assays are performed in
a nanoliter scale, which allows for sensitive detection of mAb
secretion within hours of cell loading. We showed IgG secretion
rankings correlated with mAb titer from standard expression
cultures, and we saw a promising correlation of on‐chip antigen
binding with binding affinity from purified antibodies. Combined with
a transient transfection process, our on‐chip assays shorten the
timeline for screening IgG expression and binding to 3 days. These
results suggest that the platform technology could potentially be
used as a prescreen to quickly narrow down engineered panels by
deselecting poor expressors and poor binders. To further develop
mAb optimization on the platform, we are developing novel
processes for Kd binding affinity assays, koff kinetic assays, and cell‐
based functional assays.
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7 | DEVELOPMENT OF A QUANTITATIVE
SINGLE ‐CELL ASSAY
To further expand the utility of the Beacon platform, we explored
a variety of library formats, with yeast display as a primary focus
due to its wide versatility to perform protein and peptide
engineering (Cherf & Cochran, 2015). Yeast display has been
used to discover de novo binders (McMahon et al., 2018; Wang
et al., 2016), affinity mature existing binders (Tiller et al., 2017),
engineer in pH‐sensitivity (Schroter et al., 2015), improve protein
thermal stability (Jones, Tsai, & Cochran, 2011), and enhance
enzyme kinetics (I. Chen, Dorr, & Liu, 2011). Our work used
yeast‐displayed peptides isolated from an affinity maturation
campaign against a receptor ECD to develop a binding affinity
assay on the platform. The precise cell manipulation on the
Beacon via OEP facilitated the development of a single‐cell assay
even for small‐sized cells such as yeast (diameter 5 microns). The
binding affinity assay is schematically summarized in Figure 6a.
First, six different fluorescein‐labeled yeast displaying peptides
were loaded and penned sequentially in specified chip regions,
F IGURE 5 Engineered antibody screening | (a) Optimization of the transient process demonstrates robust detection of secreted antibody 24 hr
posttransfection. Bead‐based IgG assay was sequentially run 2 hr (Assay A) and 24 hr (Assay B) after cell loading to assess the antibody secretion
levels over time. (b) Bead‐based IgG secretion rankings of 10 different anti‐G‐protein‐coupled receptors (GPCR) antibodies accurately correlate with
the FortéBio titers of standard production cultures for both stable CHO and HEK 293‐6E cell hosts. (c) IgG‐ and antigen‐specific diffusion assays
enable differentiation of high affinity vs. low affinity anti‐GPCR antibodies. Binding affinity is calculated via the assessment of the remaining amount
of labeled peptide and antigen, pseudocolored in magenta. CHO, Chinese hamster ovary [Color figure can be viewed at wileyonlinelibrary.com]
JORGOLLI ET AL. | 2403
Figure 6b. Single cells were loaded in individual pens to enable
accurate signal detection. Next, the lowest concentration of
Alexa Fluor 647‐labeled receptor ECD was imported and
incubated for 10 min. After incubation, the binding of receptor
ECD to yeast‐displayed peptide was assayed through multiplex
image acquisition: bright field ‐ displaying the cell position, FITC ‐
quantifying the concentration of displayed peptide, and Cy5 ‐
quantifying the concentration of the bound receptor. To measure
the binding affinity, we ran a series of specified antigen
concentrations sequentially from 0.125 to 1 µg/ml on the chip.
We developed internal analysis software to quantify the peptide
affinity at the single‐cell level via signal‐to‐noise ratio (SNR) analysis,
Figure 6c. Accurate quantification of relative binding affinity via SNR
was based on integrated multiplexed signal readout and background
analysis taking into account the fluorescent background from the
unbound receptor ECD. Figure 6d summarizes the results of one of
F IGURE 6 Single‐cell quantitative assay | (a) Workflow schematic: After loading, cells are identified and trapped into light cages facilitating single‐
cell penning via OEP. Next, low concentration (0.125 µg/ml) of dye‐labeled (A647) target (receptor ECD) is imported and incubated for 10min
followed by multiplexed image acquisition (bright field, FITC, and Cy5). The process is reiterated at increasing target concentrations up to 1 µg/ml.
(b) Loaded and penned six different yeast‐displayed peptides (P1–P6), previously induced, in specified chip region shown in different colors.
Bar = 150 µm. (c) Representative fluorescent image used to quantify the concentration of bound receptor to peptides displayed on individual yeast
cells; Schematic of the automated data analysis SNR: Fluorescence intensity of individual cells (circled in red) is normalized by the fluorescence
intensity of the background via the creation of a doughnut region (gray) around each region of interest. Bar = 50 µm. (d) Relative ranking of binding
affinity: S/N Ratio plotted versus a series of receptor ECD concentrations from 0.125 to 1 µg/ml. (e) GPCR binding affinity rankings (SNR) generated
on the OEP platform ‐ based on individual cell analysis ‐ were consistent with conventional measurements (FACS). ECD, extracellular domain; GPCR,
G‐protein‐coupled receptors; OEP, opto‐electro‐positioning; SNR, signal‐to‐noise ratio [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 7 Continued.
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our initial experiments where we evaluated the binding of six yeast‐
displayed peptides across a series of ECD concentrations. The
relative affinity rankings measured on the OEP platform—based on
individual cell analysis—were consistent with conventional FACS
analysis of the same constructs. In addition, we achieved on‐chip
induction of yeast library paving the way towards the development of
on‐chip functional assays.
8 | DEVELOPMENT OF GENOMIC
APPLICATIONS
With the capabilities now available for single‐cell sequencing,
integrated single‐cell analysis systems like this one will find many
applications that link up genotype to phenotype. Two recent
examples capitalize on this integration to generate and identify
CRISPR edited clones very quickly in an automated manner as well as
isolate rare cells for subsequent genotyping.
Mocciaro et al. (2018) demonstrated a method to identify, select,
and expand cell lines with desired edits in less than 10 days, a process
that would normally take 3 to 4 weeks using traditional subcloning
techniques. Using the Beacon platform, they were able to load
> 3000 single primary human T cells on an OptoSelect chip, after
electroporation of the cell population with Cas9 RNPs. After 3 days
of clonal expansion, clones were screened for the desired edits using
a surface marker. The desired edit, in this case, was designed to
replace 12 nucleotides in the CXCR4 gene, which encodes for a
transmembrane receptor protein clinically‐relevant for HIV infection.
Homozygously edited cell lines should not express the marker and
therefore a fluorescent assay using anti‐CXCR4 antibody was used to
identify nonfluorescent clones for selection. Selected clones were
exported with a process that splits each clone into two separate
exports, one for sequencing and one for proliferation. Expected edits
were confirmed by genomic DNA sequencing in some of the selected
clones, demonstrating the ability to quickly identify edited clones of
interest while simultaneously keeping a live culture ready for scaleup
(Mocciaro et al., 2018).
Beaumont et al. (2018) used the nanofluidic technology in a
similar way to connect phenotype to the genotype of single cells
taken from ovarian cancer patients. After placing ovarian tumor cell
lines in the chip, colonies of cells from each cell line were monitored
for multiple phenotypes, such as growth rate and cell surface protein
expression. Protein expression was measured by diffusing fluores-
cent antibodies into and out of the NanoPens, allowing for on‐chip
fluorescent cell staining and phenotyping. Individual cells were also
cloned and exported to well plates for subsequent processing and
sequencing with a targeted hotspot sequencing panel thus demon-
strating the compatibility of the platform with downstream nucleic
acid sequencing workflows (Beaumont et al., 2018).
9 | DEVELOPMENT OF CELL LINES FOR
PRODUCTION
The generation of a highly productive manufacturing cell line is a key
and important step in the development process for large molecule
therapeutics (Estes & Melville, 2014; Fischer, Handrick, & Otte,
2015). To select a cell line that will give high productivity, long‐term
stability, and consistent product and process consistency, subcloning
and extensive screening is required on hundreds of clonal cell lines,
measuring growth, productivity and product quality in multiple
screening assays (Wurm, 2004). In addition, regulatory agencies
require that clinical trials be initiated with material from clonally
derived cell lines and banks, so documentation that the cell line is
derived from a single cell is required to provide that assurance of
clonality (Tharmalingam et al., 2018).
Cloning was historically accomplished by limiting dilution of
stably transfected pools into 96‐well plates (Kim, Kim, & Lee, 2012).
This method has a high rate of error and requires multiple rounds of
cloning to satisfy clonality assurance required by regulatory agencies.
This traditional limiting dilution approach provides no information on
the productivity of each individual clones. Modern approaches use
FACs to deposit single cells into 96 or 384 well plates followed by
imaging of each well on the same day (DeMaria et al., 2007; Fieder,
Schulz, Gorr, Bradl, & Wenger, 2017). FACs deposition into well
plates provides both an increased assurance that a single cell is
deposited into each well and can be coupled with surface staining for
the protein of interest to enable isolation of only clones producing
high amounts of the desired protein. However, several challenges
remain. FACs exposes cells to high levels of pressure leading to
reduced viability and recovery of isolated cells. Furthermore, surface
staining methods identify protein levels retained in the plasma
membrane, but the correlation between protein retained in the
plasma membrane of the cell and amount secreted is not well
established. This approach also only measures proteins levels at a
single point in time, but protein synthesis, modification, and secretion
are a highly dynamic process that is well known to change during the
cell cycle (Alber & Suter, 2019). As a consequence of low recovery
F IGURE 7 Comparison of a microtiter plate based cloning workflow vs. a nanofluidic chip subcloning workflow. A depiction of the steps
involved in performing a clonal isolation and expansion workflow using two approaches. Differences are highlighted in boxes for FACS‐based
workflow(solid) and platform workflow (dotted). Standard subcloning operation: A heterogeneous population is isolated and deposited into
microtiter plates using FACS‐based cell sorting, followed with high‐quality, high‐throughput whole well imaging to verify a single cell in a well.
After growth and repeated imaging, colonies are picked and consolidated using automation liquid handlers. Top clones are then screened in a
bioreactor to select the final clone. In contrast, the platform workflow enables single cell isolation, growth assessment, and high‐throughput
screen on the chip (dotted box) in the nanofluidic workflow, and only those clones that meet the desired criteria are exported and expanded for
further evaluation (Le et al., 2018) [Color figure can be viewed at wileyonlinelibrary.com]
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and poor‐quality screening, a typical cloning process will use 50 to
100 or more plates to isolate and screen hundreds to thousands of
clones of single cell origin to find a suitable manufacturing line.
Manually verifying clonality, transferring and scaling up clones from
96‐well plates production scale, and performing a bench‐scale
production assessment experiment is an extremely resource‐inten-
sive endeavor. Moreover, some conventional instruments that enable
higher throughput screening of clones for cell line development are
limited to a solid media format that may not be relevant to
downstream culture conditions, while miniature bioreactors can
provide relevant culture conditions but are limited to tens of clones
at a time.
Nanofluidic technologies offer a promising solution to further
miniaturize and increase the efficiency of manufacturing cell line
generation (Sackmann, Fulton, & Beebe, 2014). Indeed, we have
demonstrated that CHO cell lines can be isolated using the Berkeley
Lights technology with high assurance of single cell origin, cultured,
screened, and exported at high efficiency (Le et al., 2018). In a head
to head comparison with a FACS‐enabled microtiter plate‐based
workflow, we were able to generation of comparable clonal cell lines
with reduced resources, summarized in Figure 7. Over all recoveries
of the clonal CHO cell lines were shown to be higher than other
methods, in part due to the improved conditions nanoscale culture
offers. A rich data set is generated to support clonality, tracking, and
population understandings to enable early decisions and identifica-
tion of highly performing cell lines. Single‐cell data obtained from cell
lines provide insights into defining population characteristics of the
production cell lines that are not currently possible with the
traditional FACS‐based methods, offering the potential to make
improved cell line choices and better predict downstream success (Le
et al., 2018).
10 | CONCLUSION
Innovation in basic science has delivered some outstanding advance-
ments to biomedical research over the last 40 years including
transgenic mice, PCR, genetic sequencing, gene editing, and many
others. Interestingly, most of these innovations were realized using
relatively simplistic cell and liquid handling technologies invented in
the 1950s: pipettes and well plates. In many cases, the pace of
applied science and technology development has been outpaced by
basic scientific progress. The traditional approach taken by those in
the field has been to utilize straight‐forward technologies at the
microscale level. These microscale approaches reach practical limits
very quickly, as the complexity of rooms filled with single‐function
equipment and automated robots still struggle with recent advances
in research methodology, particularly on individual cells at the
nanoscale fluidic regime. The promise of “lab on a chip” technology
has been slow to mature towards industrial applications, but the
promise remains the same: miniaturization of basic cellular manip-
ulations should lead to faster and more efficient discovery, requiring
less reagent and effort due to enhanced sensitivities. The platform
technology discussed here, Beacon, overcomes such limitations
through the capability to maintain physiologically‐relevant culture
environments of thousands of segregated cells while performing
numerous types of very sensitive assays all under reproducible
computer control, otherwise known as “digital cell biology”. Im-
portantly, this ability to flexibly string together multiple processes
and tests (manipulate, grow, assay, interrogate, select) on a single
system allows for full biological workflows to be performed with
significantly minimized resources.
Digital cell biology on the platform creates the opportunity to
transition many of today’s cell‐based well plate assays to a unique
new format, unlocking a step function increase in workflow scale and
speed. Complex and time‐consuming assays, like the measurement of
growth and IgG secretion rate on thousands of clones, have proven
to be straight‐forward to transfer onto the platform’s nanofluidic
environment, making them routine to run on a day to day basis. We
envision many more complex assays being reduced to routine
software‐controlled workflows, such as on‐chip functional assays
that require multiple precisely defined populations of cells interact-
ing with reporter cell‐based assays. Examples include plasma B cells
combined with reporter cells that indicate if the IgG molecule is
functional, T cell activation by dendritic cells, T cell killing of tumor
cells, or defined cell number micro‐organoids. In addition, we believe
that capture of real‐time assay kinetics of single cells or cell clones
across time and across multiple assay types for the same cell
population will enable opportunities to discover and rank individual
clones that previously relied on single snapshots of the population in
time, like FACS and ELISA. Measuring cell surface protein expression,
protein secretion, metabolic profile in addition to RNA‐seq from the
same individual cell will enable researchers to build deep profiles or
cell “fingerprints”, unlocking novel insights at the individual cell level.
Combining the power of machine learning and AI with digital cell
biology offers additional power to unlock deep insights into
mechanistic biology that has thus far proven elusive at the macro
scale. This technology can be applied to many areas within biopharma
including antibody discovery, assay development, antibody engineer-
ing, and cell line development. With the ability to select the right
cells, the technology can also be applied in the future to cell therapy
manufacturing as well as workflows within synthetic biology, and
diagnostics. We believe digital cell biology platforms will prove to be
transformative to multiple industries that require a dramatic step
forward in speed and scale to realize the next wave of breakthroughs.
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